Emergent BioSolutions Inc.
EBS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001367644
In the last 90 days, Emergent BioSolutions Inc. insiders filed 0 open-market purchases and 1 sale; 194 institutions reported holding it in 13F filings for Q2 2026, worth $373.6M in total; no superinvestor holds it.
Holders of 5% or more of EBS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Emergent BioSolutions Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G | 7.30%3.98M shares | New | Jul 17, 20251 filing | Jul 17, 2025 | SEC |
| State Street Corp | 13G | 5.10%2.70M shares | New | Feb 9, 20261 filing | Feb 9, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
4 Schedule 13D and 13G filings on Emergent BioSolutions Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 20266:02 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −6.76 ppfrom 6.76%Below 5% | Mar 13, 2026 | SEC |
| Feb 9, 20266:33 AM ET | State Street Corp | 13G | 5.10%2.70M shares | New | Dec 31, 2025 | SEC |
| Jan 30, 20261:31 PM ET | Vanguard Group Inc | 13G/A | 6.76%3.55M shares | – | Dec 31, 2025 | SEC |
| Jul 17, 20257:54 PM ET | BlackRock, Inc. | 13G | 7.30%3.98M shares | New | Jun 30, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Emergent BioSolutions Inc. shares.
No Form 144 notices for Emergent BioSolutions Inc. are on file.